Roche Holding, CH0012032048

Roche Holding stock gains support from a moderate buy view

Published on 09/18/2026 at 13:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding stock drew a Moderate Buy consensus on September 18, 2026, from 12 analysts. The shares closed at USD 54.63 on September 17, 2026, with a USD 348.02 billion market value.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding AG (CH0012032048) stock had a consensus rating of Moderate Buy on September 18, 2026, after MarketBeat said 12 analysts covered the shares and split evenly between 6 buys and 6 holds. The same page put the average twelve-month price objective at USD 60.00.

Analysts keep the upside capped

MarketBeat also said on September 18, 2026, that Morgan Stanley had upgraded Roche to overweight with a USD 63.00 price objective on August 7, 2026, while HSBC reaffirmed hold on September 10, 2026. That leaves the average target only 9.8 percent above the USD 54.63 opening level quoted on the same page.

Roche's U.S. quote stood at USD 54.63 on September 17, 2026, after a decline of 0.94 percent, with a market capitalization of USD 348.02 billion and volume of 1.23 million shares. The 52-week range was USD 39.50 to USD 60.85.

Boston and lymphoma data

MarketBeat said on September 18, 2026, that Roche and Genentech opened an Innovation Center in Boston focused on cardiovascular, renal and metabolic diseases. The same site also highlighted positive Phase III CELESTIMO data for Lunsumio in follicular lymphoma and a bispecific-antibody research partnership with Dualitas Therapeutics.

For investors, the number that matters is the spread between the USD 54.63 quote and the USD 60.85 52-week high. The stock is still 10.2 percent below that peak.

Price and market view

Roche stock ended at USD 54.63 on September 17, 2026, with a 52-week low of USD 39.50 and a market capitalization of USD 348.02 billion. The current setup leaves the shares between a cautious analyst base and a recent run of pipeline headlines.